future use of antiangiogenic agents in nsclc
Published 6 years ago • 35 plays • Length 2:32Download video MP4
Download video MP3
Similar videos
-
2:07
using antiangiogenic therapy in nsclc in the future
-
1:59
antiangiogenic therapy in nsclc
-
5:48
antiangiogenic therapy in nsclc: addressing the unknown
-
6:01
future directions for antiangiogenic therapy in lung cancer
-
2:37
considerations for antiangiogenic therapy in nsclc
-
2:08
research investigates role of antiangiogenic agents and checkpoint inhibitors in egfr nsclc
-
1:11
unanswered questions regarding the use of io in nsclc
-
1:00
dr. husain on the future of monitoring t790m in lung cancer
-
2:19
the future of anti-pd-1 therapies in the nsclc treatment landscape
-
3:05
rationale behind antiangiogenic therapy in nsclc
-
1:07
dr. garon on differences between antiangiogenic agents in lung cancer
-
1:36
the future of arginine deprivation therapy in lung cancer
-
3:04
final thoughts on targeted therapy and i/o agents in nsclc
-
3:56
antiangiogenic antibodies vs tkis in nsclc
-
1:22
dr. bauml on the use of immunotherapy in oligometastatic nsclc
-
3:36
angiogenesis inhibition in lung cancer
-
6:11
patient selection for ramucirumab in nsclc
-
0:57
what the future holds for antibodies in treating nsclc
-
1:25
dr. garon on antiangiogenic agents in lung cancer